Immatics NV (Immatics NV) NonCurrent Deferred Liabilities : $99.30 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immatics NV NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Immatics NV's non-current deferred liabilities for the quarter that ended in Mar. 2024 was $99.30 Mil.

Immatics NV NonCurrent Deferred Liabilities Historical Data

The historical data trend for Immatics NV's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immatics NV NonCurrent Deferred Liabilities Chart

Immatics NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

113.23

103.98

54.49

80.25

125.98

Immatics NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															69.89	58.03	58.55	125.98	99.30

Immatics NV NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Immatics NV's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Immatics NV (Immatics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immatics NV (NAS:IMTX) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

4A3:Germany

Address

Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.immatics.com

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.